Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Fast Track Articles
  5. Fast Track Article
image of Expanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy

Abstract

Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder caused by mutations in the DMD gene, leading to progressive muscle degeneration, loss of ambulation, cardiomyopathy, and early mortality. While advances in multidisciplinary care and pharmacological interventions, including corticosteroids and exon-skipping therapies, have improved patient outcomes, current treatments primarily provide symptomatic relief without addressing the underlying genetic defect. Gene therapy has emerged as a promising approach to modify disease progression, particularly through the use of adeno-associated virus (AAV)-mediated delivery of micro-dystrophin constructs. These truncated genes retain essential functional domains, enabling the restoration of dystrophin expression within the packaging limits of AAV vectors. Early-phase clinical trials have demonstrated encouraging safety profiles and transgene expression; however, challenges such as immune responses, variability in functional improvement, and long-term durability remain. Recent innovations, including optimized AAV capsids, immunomodulatory strategies, and genome editing technologies like CRISPR-Cas9, are actively being explored to overcome these barriers. Additionally, scalable vector manufacturing and the integration of real-world data are essential for broader clinical translation. This review synthesizes current advancements, clinical milestones, and future directions in gene therapy for DMD, emphasizing the need for precise dosing, long-term efficacy, and equitable access to fully realize the therapeutic potential of these evolving strategies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128386290250507101412
2025-05-21
2025-06-17

  • From This Site

    /content/journals/cpd/10.2174/0113816128386290250507101412
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Mah J.K. Korngut L. Dykeman J. Day L. Pringsheim T. Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 2014 24 6 482 491 10.1016/j.nmd.2014.03.008 24780148
    [Google Scholar]
  2. Hoffman E.P. Brown R.H. Jr Kunkel L.M. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 1987 51 6 919 928 10.1016/0092‑8674(87)90579‑4 3319190
    [Google Scholar]
  3. Gawor M. Prószyński T.J. The molecular cross talk of the dystrophin–glycoprotein complex. Ann. N. Y. Acad. Sci. 2018 1412 1 62 72 10.1111/nyas.13500 29068540
    [Google Scholar]
  4. Ervasti J.M. Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991 66 6 1121 1131 10.1016/0092‑8674(91)90035‑W 1913804
    [Google Scholar]
  5. Belhasan D.C. Akaaboune M. The role of the dystrophin glycoprotein complex on the neuromuscular system. Neurosci. Lett. 2020 722 134833 10.1016/j.neulet.2020.134833 32057921
    [Google Scholar]
  6. Bushby K. Finkel R. Birnkrant D.J. Case L.E. Clemens P.R. Cripe L. Kaul A. Kinnett K. McDonald C. Pandya S. Poysky J. Shapiro F. Tomezsko J. Constantin C. DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 9 1 77 93 10.1016/S1474‑4422(09)70271‑6 19945913
    [Google Scholar]
  7. Birnkrant D.J. Bushby K. Bann C.M. Alman B.A. Apkon S.D. Blackwell A. Case L.E. Cripe L. Hadjiyannakis S. Olson A.K. Sheehan D.W. Bolen J. Weber D.R. Ward L.M. DMD Care Considerations Working Group Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018 17 4 347 361 10.1016/S1474‑4422(18)30025‑5 29395990
    [Google Scholar]
  8. Czifrus E. Berlau D.J. Corticosteroids for the treatment of Duchenne muscular dystrophy: A safety review. Expert Opin. Drug Saf. 2024 23 10 1237 1247 10.1080/14740338.2024.2394578 39152782
    [Google Scholar]
  9. Ryder S. Leadley R.M. Armstrong N. Westwood M. de Kock S. Butt T. Jain M. Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review. Orphanet J. Rare Dis. 2017 12 1 79 10.1186/s13023‑017‑0631‑3 28446219
    [Google Scholar]
  10. Srivastava S. Anbiaee R. Houshyari M. Laxmi Sridhar S.B. Ashique S. Hussain S. Kumar S. Taj T. Akbarnejad Z. Taghizadeh-Hesary F. Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance. Cancer Cell Int. 2025 25 1 89 10.1186/s12935‑025‑03721‑1 40082966
    [Google Scholar]
  11. Mendell J.R. Rodino-Klapac L.R. Sahenk Z. Roush K. Bird L. Lowes L.P. Alfano L. Gomez A.M. Lewis S. Kota J. Malik V. Shontz K. Walker C.M. Flanigan K.M. Corridore M. Kean J.R. Allen H.D. Shilling C. Melia K.R. Sazani P. Saoud J.B. Kaye E.M. Eteplirsen Study Group Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 2013 74 5 637 647 10.1002/ana.23982 23907995
    [Google Scholar]
  12. Takeda S. Clemens P.R. Hoffman E.P. Exon-skipping in duchenne muscular dystrophy. J. Neuromuscul. Dis. 2021 8 s2 S343 S358 10.3233/JND‑210682 34180420
    [Google Scholar]
  13. Patterson G. Conner H. Groneman M. Blavo C. Parmar M.S. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach. Eur. J. Pharmacol. 2023 947 175675 36963652
    [Google Scholar]
  14. Ahmet A. Tobin R. Dang U.J. Rooman R. Guglieri M. Clemens P.R. Hoffman E.P. Ward L.M. Adrenal suppression from vamorolone and prednisone in duchenne muscular dystrophy: Results from the phase 2b clinical trial. J. Clin. Endocrinol. Metab. 2025 110 2 334 344 10.1210/clinem/dgae521 39097643
    [Google Scholar]
  15. Duan D. Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther. 2018 28 701 703 10.1016/j.ymthe.2018.07.011
    [Google Scholar]
  16. Anthony K. Feng L. Arechavala-Gomeza V. Guglieri M. Straub V. Bushby K. Cirak S. Morgan J. Muntoni F. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen. Hum. Gene Ther. Methods 2012 23 5 336 345 10.1089/hgtb.2012.117 23075107
    [Google Scholar]
  17. Mendell J.R. Sahenk Z. Lehman K. Nease C. Lowes L.P. Miller N.F. Iammarino M.A. Alfano L.N. Nicholl A. Al-Zaidy S. Lewis S. Church K. Shell R. Cripe L.H. Potter R.A. Griffin D.A. Pozsgai E. Dugar A. Hogan M. Rodino-Klapac L.R. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy. JAMA Neurol. 2020 77 9 1122 1131 10.1001/jamaneurol.2020.1484 32539076
    [Google Scholar]
  18. Mendell J.R. Shieh P.B. McDonald C.M. Sahenk Z. Lehman K.J. Lowes L.P. Reash N.F. Iammarino M.A. Alfano L.N. Sabo B. Woods J.D. Skura C.L. Mao H.C. Staudt L.A. Griffin D.A. Lewis S. Wang S. Potter R.A. Singh T. Rodino-Klapac L.R. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front. Cell Dev. Biol. 2023 11 1167762 10.3389/fcell.2023.1167762 37497476
    [Google Scholar]
  19. Lutsyk K. Gicquel T. Cortial L. Forget S. Braun S. Boyer P.O. Laugel V. Blin O. Does gene therapies clinical research in rare diseases reflects the competitivity of the country: Example of France. Therapie 2024 79 5 505 518 10.1016/j.therap.2024.01.007 38458946
    [Google Scholar]
  20. Rodríguez-Márquez E. Meumann N. Büning H. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy. Expert Opin. Biol. Ther. 2021 21 6 749 766 10.1080/14712598.2021.1865303 33331201
    [Google Scholar]
  21. Chen G. Wei T. Yang H. Li G. Li H. CRISPR-based therapeutic gene editing for duchenne muscular dystrophy: Advances, challenges and perspectives. Cells 2022 11 19 2964 10.3390/cells11192964 36230926
    [Google Scholar]
  22. Nelson C.E. Hakim C.H. Ousterout D.G. Thakore P.I. Moreb E.A. Rivera R.M.C. Madhavan S. Pan X. Ran F.A. Yan W.X. Asokan A. Zhang F. Duan D. Gersbach C.A. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016 351 6271 403 407 10.1126/science.aad5143 26721684
    [Google Scholar]
  23. Chang M. Cai Y. Gao Z. Chen X. Liu B. Zhang C. Yu W. Cao Q. Shen Y. Yao X. Chen X. Sun H. Duchenne muscular dystrophy: Pathogenesis and promising therapies. J. Neurol. 2023 270 8 3733 3749 10.1007/s00415‑023‑11796‑x 37258941
    [Google Scholar]
  24. Duan D. Micro-dystrophin gene therapy goes systemic in duchenne muscular dystrophy patients. Hum. Gene Ther. 2018 29 7 733 736 10.1089/hum.2018.012 29463117
    [Google Scholar]
  25. Wang D. Tai P.W.L. Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019 18 5 358 378 10.1038/s41573‑019‑0012‑9 30710128
    [Google Scholar]
  26. Fatima R. Khan Y. Maqbool M. Ramalingam P.S. Khan M.G. Bisht A.S. Hussain M.S. Amyloid-β clearance with monoclonal antibodies: Transforming Alzheimer’s treatment. Curr. Protein Pept. Sci. 2025 10.2174/0113892037362037250205143911 39980294
    [Google Scholar]
  27. Calcedo R. Vandenberghe L.H. Gao G. Lin J. Wilson J.M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 2009 199 3 381 390 10.1086/595830 19133809
    [Google Scholar]
  28. Arruda V.R. Xiao W. It’s all about the clothing: Capsid domination in the adeno‐associated viral vector world. J. Thromb. Haemost. 2007 5 1 12 15 10.1111/j.1538‑7836.2006.02262.x 17239162
    [Google Scholar]
  29. Colella P. Ronzitti G. Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 2018 8 87 104 10.1016/j.omtm.2017.11.007 29326962
    [Google Scholar]
  30. Chamberlain JR Chamberlain JS Progress toward gene therapy for duchenne muscular dystrophy. Mol Ther. 2017 25 5 1125 10.1016/j.ymthe.2017.02.019
    [Google Scholar]
  31. Wang Z. Tapscott S.J. Chamberlain J.S. Storb R. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front. Microbiol. 2011 2 201 21980317
    [Google Scholar]
  32. Hussain M.S. Gupta G. Samuel V.P. Almalki W.H. Kazmi I. Alzarea S.I. Saleem S. Khan R. Altwaijry N. Patel S. Patel A. Singh S.K. Dua K. Immunopathology of herpes simplex virus-associated neuroinflammation: Unveiling the mysteries. Rev. Med. Virol. 2024 34 1 e2491 37985599
    [Google Scholar]
  33. Kornegay JN Li J Bogan JR Bogan DJ Chen C Zheng H Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther. 2010 18 8 1501 10.1038/mt.2010.94
    [Google Scholar]
  34. Hinderer C. Katz N. Buza E.L. Dyer C. Goode T. Bell P. Richman L.K. Wilson J.M. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 2018 29 3 285 298 29378426
    [Google Scholar]
  35. Mingozzi F. High K.A. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood 2013 122 1 23 36 23596044
    [Google Scholar]
  36. Mueller C. Chulay J.D. Trapnell B.C. Humphries M. Carey B. Sandhaus R.A. McElvaney N.G. Messina L. Tang Q. Rouhani F.N. Campbell-Thompson M. Fu A.D. Yachnis A. Knop D.R. Ye G.J. Brantly M. Calcedo R. Somanathan S. Richman L.P. Vonderheide R.H. Hulme M.A. Brusko T.M. Wilson J.M. Flotte T.R. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Invest. 2013 123 12 5310 5318 24231351
    [Google Scholar]
  37. Buchlis G. Podsakoff G.M. Radu A. Hawk S.M. Flake A.W. Mingozzi F. High K.A. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012 119 13 3038 3041 10.1182/blood‑2011‑09‑382317 22271447
    [Google Scholar]
  38. Rogers G.L. Martino A.T. Aslanidi G.V. Jayandharan G.R. Srivastava A. Herzog R.W. Innate immune responses to AAV vectors. Front. Microbiol. 2011 2 194 21954398
    [Google Scholar]
  39. Uematsu S. Akira S. Toll-like receptors and Type I interferons. J. Biol. Chem. 2007 282 21 15319 15323 17395581
    [Google Scholar]
  40. Wright JF Codon modification and PAMPs in clinical AAV vectors: The tortoise or the hare? Mol Ther. 2020 28 3 701 10.1016/j.ymthe.2020.01.026
    [Google Scholar]
  41. Martino A.T. Suzuki M. Markusic D.M. Zolotukhin I. Ryals R.C. Moghimi B. Ertl H.C. Muruve D.A. Lee B. Herzog R.W. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011 117 24 6459 6468 21474674
    [Google Scholar]
  42. Faust S.M. Bell P. Cutler B.J. Ashley S.N. Zhu Y. Rabinowitz J.E. Wilson J.M. CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Invest. 2013 123 7 2994 3001 23778142
    [Google Scholar]
  43. Matthews E. Brassington R. Kuntzer T. Jichi F. Manzur A.Y. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Libr. 2016 2016 6 CD003725 10.1002/14651858.CD003725.pub4 27149418
    [Google Scholar]
  44. Rosenberg A.S. Puig M. Nagaraju K. Hoffman E.P. Villalta S.A. Rao V.A. Wakefield L.M. Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. Sci. Transl. Med. 2015 7 299 299rv4 10.1126/scitranslmed.aaa7322 26246170
    [Google Scholar]
  45. Mack DL Poulard K Goddard MA Latournerie V Snyder JM Grange RW Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther 2017 25 839 854 10.1016/j.ymthe.2017.02.004
    [Google Scholar]
  46. Jensen T.L. Gøtzsche C.R. Woldbye D.P.D. Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Front. Mol. Neurosci. 2021 14 695937 10.3389/fnmol.2021.695937 34690692
    [Google Scholar]
  47. Hordeaux J Wang Q Katz N Buza EL Bell P Wilson JM The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther 2018 26 3 664 10.1016/j.ymthe.2018.01.018
    [Google Scholar]
  48. Boisgerault F. Mingozzi F. The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer. Curr. Gene Ther. 2015 15 4 381 394 10.2174/1566523215666150630121750 26122097
    [Google Scholar]
  49. Le Guiner C. Servais L. Montus M. Larcher T. Fraysse B. Moullec S. Allais M. François V. Dutilleul M. Malerba A. Koo T. Thibaut J.L. Matot B. Devaux M. Le Duff J. Deschamps J.Y. Barthelemy I. Blot S. Testault I. Wahbi K. Ederhy S. Martin S. Veron P. Georger C. Athanasopoulos T. Masurier C. Mingozzi F. Carlier P. Gjata B. Hogrel J.Y. Adjali O. Mavilio F. Voit T. Moullier P. Dickson G. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat. Commun. 2017 8 16105 28742067
    [Google Scholar]
  50. Chandler R.J. LaFave M.C. Varshney G.K. Trivedi N.S. Carrillo-Carrasco N. Senac J.S. Wu W. Hoffmann V. Elkahloun A.G. Burgess S.M. Venditti C.P. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 2015 125 2 870 880 10.1172/JCI79213 25607839
    [Google Scholar]
  51. Russell D.W. Grompe M. Adeno-associated virus finds its disease. Nat. Genet. 2015 47 10 1104 1105 26417859
    [Google Scholar]
  52. Nathwani A.C. Reiss U.M. Tuddenham E.G.D. Rosales C. Chowdary P. McIntosh J. Della Peruta M. Lheriteau E. Patel N. Raj D. Riddell A. Pie J. Rangarajan S. Bevan D. Recht M. Shen Y.M. Halka K.G. Basner-Tschakarjan E. Mingozzi F. High K.A. Allay J. Kay M.A. Ng C.Y.C. Zhou J. Cancio M. Morton C.L. Gray J.T. Srivastava D. Nienhuis A.W. Davidoff A.M. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 2014 371 21 1994 2004 10.1056/NEJMoa1407309 25409372
    [Google Scholar]
  53. Gil-Farina I Fronza R Kaeppel C Lopez-Franco E Ferreira V D'Avola D Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther. 2016 24 16 1100 1105 10.1038/mt.2016.52
    [Google Scholar]
  54. Keeler A.M. Flotte T.R. Recombinant adeno-associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): Where are we, and how did we get here? Annu. Rev. Virol. 2019 6 1 601 621 10.1146/annurev‑virology‑092818‑015530 31283441
    [Google Scholar]
  55. Shen W. Liu S. Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front. Immunol. 2022 13 1001263 36389770
    [Google Scholar]
  56. Youssef E. Fletcher B. Palmer D. Enhancing precision in cancer treatment: The role of gene therapy and immune modulation in oncology. Front. Med. (Lausanne) 2025 11 1527600 10.3389/fmed.2024.1527600 39871848
    [Google Scholar]
  57. Sandoval-Villegas N. Nurieva W. Amberger M. Ivics Z. Contemporary transposon tools: A review and guide through mechanisms and applications of Sleeping Beauty, piggyBac and Tol2 for genome engineering. Int. J. Mol. Sci. 2021 22 10 5084 10.3390/ijms22105084 34064900
    [Google Scholar]
  58. Hanson B. Wood M.J.A. Roberts T.C. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. RNA Biol. 2021 18 7 1048 1062 10.1080/15476286.2021.1874161 33472516
    [Google Scholar]
  59. Fatehi S. Marks R.M. Rok M.J. Perillat L. Ivakine E.A. Cohn R.D. Advances in CRISPR/Cas9 genome editing for the treatment of muscular dystrophies. Hum. Gene Ther. 2023 34 9-10 388 403 10.1089/hum.2023.059 37119122
    [Google Scholar]
  60. Martínez-Molina E. Chocarro-Wrona C. Martínez-Moreno D. Marchal J.A. Boulaiz H. Large-scale production of lentiviral vectors: Current perspectives and challenges. Pharmaceutics 2020 12 11 1051 10.3390/pharmaceutics12111051 33153183
    [Google Scholar]
  61. Tripathi N.K. Shrivastava A. Recent developments in bioprocessing of recombinant proteins: Expression hosts and process development. Front. Bioeng. Biotechnol. 2019 7 420 10.3389/fbioe.2019.00420 31921823
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128386290250507101412
Loading
Expanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy
Bentham Science Publishers ; https://doi.org/10.2174/0113816128386290250507101412
/content/journals/cpd/10.2174/0113816128386290250507101412
/content/journals/cpd/10.2174/0113816128386290250507101412
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: AAV Vectors, clinical trials, CRISPR-Cas9, dystrophin, gene editing, micro-dystrophin, transgene expression 

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test